Results 151 to 160 of about 165,269 (210)

Association between serum branched chain amino acids, mammalian target of rapamycin levels and the risk of gestational diabetes mellitus: a 1:1 matched case control study. [PDF]

BMC Pregnancy Childbirth
Cui L, Li Z, Liu X, Li Z, Li J, Guo Y, Zhou H, Yang X, Zhang Z, Gao Y, Ren L, Hua L.   +11 more
europepmc   +1 more source

Hypoxia drives CBR4 down-regulation promotes gastroenteropancreatic neuroendocrine tumors via activation mammalian target of rapamycin mediated by fatty acid synthase. [PDF]

J Cell Commun Signal
Ye M, Xu L, Lu F, Chen L, Hu C, Chen J, Xue B, Gu D, Xu R, Xu Y, Yu P, Wang Y, Tian Y, Zhu G, Tang Q.   +14 more
europepmc   +1 more source

Zinc finger and broad-complex, tramtrack, and bric-a-brac domain containing 16 silencing attenuates bleomycin-induced pulmonary fibrosis in mice through inhibition of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin pathway. [PDF]

Cytojournal
Fang X, Wen X, Zhou L, Jiang Y, Wang L.
europepmc   +1 more source

The Conversion From Mycophenolic Acid to Mammalian Target of Rapamycin Inhibitor Reduces the Incidence of Cytomegalovirus Replication in Belatacept-Treated Kidney-Transplant Recipients. [PDF]

Kidney Int Rep
Del Bello A, Cachoux J, Abravanel F, Prudhomme T, Kamar N.   +4 more
europepmc   +1 more source

Retracted: MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2). [PDF]

Med Sci Monit
Li N, Han M, Zhou N, Tang Y, Tang XS.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mammalian target of rapamycin

Seminars in Oncology, 2004
Targeted molecular therapeutics are tailored toward the genetic abnormalities that cause tumor progression. Modulation of certain signaling pathways that are aberrant in cancer cells has the potential to provide an effective, nontoxic approach to therapy in a broad range of cancers. Agents targeting BCR-ABL (imatinib mesylate [formerly known as STI-571]
Funda, Meric-Bernstam, Gordon B, Mills
openaire   +2 more sources

Mammalian Target of Rapamycin Inhibitor-Associated Stomatitis

Future Oncology, 2013
With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects.
Boers-Doets, C.B., Raber-Durlacher, J.E., Treister, N.S., Epstein, J.B., Arends, A.B.P., Wiersma, D.R., Lalla, R.V., Logan, R.M., van Erp, N.R.P., Gelderblom, H.   +9 more
openaire   +5 more sources

Targeting the mammalian target of rapamycin in myxoid chondrosarcoma

Anti-Cancer Drugs, 2008
Myxoid chondrosarcoma is a slow-growing sarcoma poorly responsive to chemotherapy and radiation therapy. Translational research has validated several proteins as optional therapeutic targets. Significant responses are, however, rare. In this paper we report an extraordinary response of myxoid chondrosarcoma to targeted therapy by rapamycin in ...
Ofer, Merimsky, Rinat, Bernstein-Molho, Ronit, Sagi-Eisenberg   +2 more
openaire   +2 more sources

Mammalian target of rapamycin (mTOR) inhibitors

Current Oncology Reports, 2004
Current efforts in anticancer drug development are targeting key factors in cell-cycle regulation. Mammalian target of rapamycin (mTOR) is one such protein kinase that facilitates cell growth by stimulating the cell to traverse the G1 to S phase of the cell cycle.
openaire   +2 more sources